Trial Profile
Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs HBAI 20 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Acronyms BE-Responder
- Sponsors CyTuVax
- 01 Oct 2021 Results published in the Liver International
- 17 Jun 2019 Primary endpoint has been met (immunogenicity of the adjuvanted vaccine), according to a CyTuVax media release.
- 17 Jun 2019 Results published in a CyTuVax media release.